Financial Data and Key Metrics Changes - Revenue increased by 6.7% compared to the prior year quarter, with net income attributable to HCA Healthcare rising almost 31% [4][11] - Diluted earnings per share as adjusted increased by 29%, and adjusted EBITDA grew around 11% versus the prior year period [4][11] - For the full year 2025, consolidated adjusted EBITDA increased by 12.1% over the prior year, with a 90 basis point improvement in adjusted EBITDA margins [11] Business Line Data and Key Metrics Changes - Same-facility admissions increased by 2.4%, and equivalent admissions increased by 2.5%, aligning with expectations of 2%-3% growth [9] - Inpatient surgeries were flat, while outpatient surgical volume decreased slightly [9] - ER visits increased by 50 basis points, with overall respiratory volumes having no material impact on year-over-year volume [9] Market Data and Key Metrics Changes - Same facility total commercial equivalent admissions increased by 1.1% over the prior year, with Medicare increasing by 3.5% and Medicaid by 2.2% [9][10] - Same-facility net revenue per equivalent admission increased by 2.9% versus the prior year quarter [10] Company Strategy and Development Direction - The company is focused on network expansion, workforce development, and clinical capabilities, which have contributed to positive outcomes across the HCA Healthcare system [5][6] - The Resiliency Program was strengthened in organizational capabilities, competitive positioning, and financial management, aiming to navigate policy dynamics effectively [6] - The company plans to invest significantly in technology and digital innovation strategies to deliver long-term value [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the core business, forecasting volumes in a long-term growth range of 2%-3% [6] - The company anticipates adverse impacts on adjusted EBITDA between $600 million and $900 million related to health insurance exchanges due to administrative reforms and the expiration of enhanced premium tax credits [14] - Management remains optimistic about operational performance and believes the company is well-positioned for continued progress in 2026 [16] Other Important Information - Capital expenditures totaled $1.5 billion in the quarter and $4.9 billion for the year, with a new $10 billion share repurchase program authorized by the board [11][15] - The quarterly dividend was increased from $0.72 to $0.78 per share [15] Q&A Session Summary Question: Can you talk about the expense items and margin improvement opportunities for 2026? - Management indicated expectations for stable margins in 2026, with continued physician cost pressures anticipated [19][20] Question: Can you provide more detail on the resiliency programs and their impact? - The resiliency program focuses on revenue integrity, cost efficiencies, and capacity management, with a target of $400 million in incremental cost savings for 2026 [24][25] Question: What is the expected impact of the health insurance exchange headwinds on volume? - Management anticipates a 15%-20% decline in HIX volumes for 2026, with a significant portion migrating to uninsured status, leading to a decline in utilization [26][66] Question: Can you elaborate on the pause of Texas Medicaid supplemental payments? - The Texas Medicaid program is under review, and its potential reinstatement could impact the overall guidance for 2026 [96] Question: What are the expectations for growth in specialties and procedures in 2026? - Management noted reasonable demand for cardiac services and emphasized investments in emergency room services and outpatient facilities [88][89]